We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Eli Lilly Beats Dr. Reddy's In Cancer Drug Patent Suit

Law360 (June 22, 2018, 11:08 PM EDT) -- A drug product for which Dr. Reddy’s is seeking U.S. Food and Drug Administration approval would infringe an Eli Lilly and Co. patent covering best-selling cancer treatment Alimta, an Indiana federal judge found Friday following a bench trial, ruling that the two drug products are equivalent.

U.S. District Judge Tanya Walton Pratt agreed with Eli Lilly that Dr. Reddy’s Laboratories Inc.’s use of pemetrexed ditromethamine in a drug product described in its new drug application with the FDA infringes under the doctrine of equivalents Eli Lilly’s...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.